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Abstract
Background: The REACH-HF (Rehabilitation EnAblement in CHronic Heart Failure) trial found that the REACH-HF
home-based cardiac rehabilitation intervention resulted in a clinically meaningful improvement in disease-specific health-
related quality of life in patients with reduced ejection fraction heart failure (HFrEF). The aims of this study were to
assess the long-term cost-effectiveness of the addition of REACH-HF intervention or home-based cardiac rehabilitation
to usual care compared with usual care alone in patients with HFrEF.
Design and methods: A Markov model was developed using a patient lifetime horizon and integrating evidence from
the REACH-HF trial, a systematic review/meta-analysis of randomised trials, estimates of mortality and hospital admis-
sion and UK costs at 2015/2016 prices. Taking a UK National Health and Personal Social Services perspective we report
the incremental cost per quality-adjusted life-year (QALY) gained, assessing uncertainty using probabilistic and deter-
ministic sensitivity analyses.
Results: In base case analysis, the REACH-HF intervention was associated with per patient mean QALY gain of 0.23 and
an increased mean cost of £400 compared with usual care, resulting in a cost per QALY gained of £1720. Probabilistic
sensitivity analysis indicated a 78% probability that REACH-HF is cost effective versus usual care at a threshold of
£20,000 per QALY gained. Results were similar for home-based cardiac rehabilitation versus usual care. Sensitivity
analyses indicate the findings to be robust to changes in model assumptions and parameters.
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Conclusions: Our cost-utility analyses indicate that the addition of the REACH-HF intervention and home-based
cardiac rehabilitation programmes are likely to be cost-effective treatment options versus usual care alone in patients
with HFrEF.
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Introduction
Heart failure with reduced ejection fraction (HFrEF)
represents a major health issue and is associated with
considerable morbidity and mortality. Heart failure as
primary diagnosis accounts for 1–2% of the annual
healthcare budget in Europe and the USA.1 The
global economic burden of heart failure is estimated
at $US108bn per annum with hospital admission
being a key economic driver.2
Systematic reviews and meta-analyses of cardiac
rehabilitation for heart failure have shown improve-
ments in health-related quality of life (HRQoL) and
reductions in re-hospitalisations and demonstrated
potential cost-effectiveness.3,4 This existing evidence
is based solely on hospital (or centre)-based cardiac
rehabilitation programmes and the economic evalu-
ation data are limited in both quantity and quality.3,4
In spite of national and international guidelines rec-
ommending cardiac rehabilitation for heart failure,5–7
less than 20% of heart failure patients in the UK are
referred to cardiac rehabilitation and less than 15%
currently participate in cardiac rehabilitation,8–10
prompting calls for alternative more accessible models
of cardiac rehabilitation provision.8 REACH-HF
(Rehabilitation EnAblement in CHronic Heart
Failure) is a home-based cardiac rehabilitation pro-
gramme delivered over 12 weeks by a trained healthcare
professional for patients and their caregivers. Uniquely
the REACH-HF intervention has been co-developed
with patients, caregivers and clinicians to include core
components of comprehensive cardiac rehabilitation,
that is, education and psychological support, in add-
ition to exercise training.11 The REACH-HF rando-
mised controlled trial compared the addition of
REACH-HF intervention with usual care with usual
care alone in patients with HFrEF across four UK
sites.12 At 12 months, the trial found that the
REACH-HF intervention led to a statistically signifi-
cant and clinically meaningful improvement in HRQoL
with a reduction in total Minnesota Living with Heart
Failure Questionnaire score of –5.7 points (95% confi-
dence interval (CI): –10.6 to –0.7) and a non-significant
reduction in the number of patients experiencing one or
more hospital admissions (odds ratio: 0.56, 95% CI:
0.13 to 2.33).13 Having estimated the average cost of
REACH-HF delivery at £418 per patient,13 we sought
to assess whether the REACH-HF intervention is
likely to be cost-effective for healthcare payers over
the long-term.
We report the results of a model-based cost-effective-
ness analysis that extrapolates the findings of the
REACH-HF trial to estimate the long-term cost-
effectiveness of REACH-HF intervention. We also
report the long-term cost-effectiveness of home-based
cardiac rehabilitation based on a meta-analysis of
randomised trials.
Methods
This analysis was reported in accord with the
Consolidated Health Economic Evaluation Reporting
Standards statement14 and the reference case of the UK
National Institute for Health and Care Excellence
(NICE).15 The analyses were conducted from the per-
spective of the UK National Health Service (NHS)
and Personal Social Services. We estimated the cost-
effectiveness of REACH-HF plus usual care versus
usual care alone and home-based cardiac rehabilitation
plus usual care versus usual care alone, based on
the estimated incremental cost per quality-adjusted
life-year (QALY) – a cost-utility analysis.
Study population
Data were used from the REACH HF trial13 where
participants with HFrEF were recruited from primary
and secondary care in four UK centres during 2015–
2016 and were randomly assigned to the REACH-HF
intervention plus usual care or usual care alone (current
standard therapy in the UK for most patients with
heart failure).12 In the UK, only a minority of patients
with heart failure receive cardiac rehabilitation and
usual care in this trial was a no cardiac rehabilitation
approach that included medical management according
to national and local guidelines, including specialist
heart failure nurse care.13 Details of the REACH-HF
intervention are presented elsewhere.12,13
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Model structure
Consistent with the economic evaluation literature
in heart failure,16 a Markov cohort model
(Supplementary Material Figure 1 online) was developed
that captured the impact on hospital admissions, and a
related increase in the mortality rate, for people with
heart failure. In this case a cohort Markov model was
considered appropriate since this estimates the average
effect of the intervention on morbidity, mortality, cost
and HRQoL. The model uses a lifetime horizon (follows
patients from a starting age of 78 to age 100 years) and
costs and QALYs were discounted at 3.5%.15
The model consisted of three primary health states:
(1) heart failure with no heart failure-related hospital
admission, (2) heart failure with heart failure-related
hospital admission, and (3) death. The model uses a
one-month cycle length, in order to capture the effects
of hospital admission events which are short term
events but may recur several times in a year. Tunnel
states are used in the model to reflect an increased mor-
tality risk in the period (1–38 months) after hospital
admission/discharge. Patients begin in a stable heart
failure health state (heart failure with no heart failure-
related hospitalisation). From this state, patients can
either remain in the same state, or experience a heart
failure-related hospitalisation or death. If the patients
experience a heart failure-related hospitalisation, they
automatically progress to the first of 38 post-hospitali-
sation tunnel states, where they will progress one state
each month until month 38 post-hospitalisation,
when they will return to the heart failure with no
heart failure-related hospitalisation state. During the
tunnel states, patients can also experience an additional
hospitalisation or death at any time. The model was
developed in Microsoft Excel and programmed in
Visual Basic for Applications.
Model inputs
The model parameters and assumptions about transi-
tions between health states are outlined in Table 1.17–27
Cardiac rehabilitation effectiveness. We used data from
REACH-HF trial for the difference in risk of hospital
admission (odds ratio: 0.56, 95% CI: 0.13 to 2.33).13
We also undertook a meta-analysis that combined
REACH-HF trial data with two other randomised
trials of home-based cardiac rehabilitation versus no car-
diac rehabilitation usual care28,29 to estimate the pooled
risk of hospital admission following home-based cardiac
rehabilitation compared with usual care (odds ratio: 0.70,
95% CI: 0.27 to 1.60) (see Supplementary Material
Figure 1 for meta-analysis forest plot and methodology).
This reduction in risk was assumed to last for four years
from the start of the model, after which hospital admis-
sion rates are assumed to return to baseline. We assessed
the impact on estimates of cost-effectiveness of variations
in this assumption using sensitivity analyses.
Hospital admissions. We applied hospital admission data
for heart failure-specific admissions from a UK cohort
study reflective of a UK primary care setting, with
patients experiencing both first and subsequent hospital
admissions20 (see Table 1). In sensitivity analyses, we
tested the robustness of model outcomes to changes in
hospital admission rates, using data from the UK
Eplerenone in Mild Patients Hospitalization and
Survival Study in Heart Failure (EMPHASIS) trial,22
which provided a lower estimate of admission rates
(10% heart failure-related admissions; 20% all cause
admissions per annum) and a meta-analysis of rando-
mised trials30 reporting relatively high admission rates
(34% heart failure-related admissions; 85% all cause
admission per annum). We used the same admission
rate for all patients in the model irrespective of age
and previous admissions.
Mortality. Survival parameters in the model are based on
a recently published analysis of UK mortality rates in
The Health Improvement Network (THIN) dataset,
1998–2012,17 a retrospective cohort of 54,313 heart fail-
ure patients aged over 45 years. In a sensitivity analysis,
we applied the overall survival reported by Mohiuddin
et al.31 for patients in another large UK cohort, who
had already experienced a hospital admission for heart
failure and therefore are expected to have a worse prog-
nosis. This study showed increased risk for time since
admission in people 0–1 months, 1–3 months, 3–6
months, 6–12 months, 12–24 months and 24–38
months after admission. The reported hazard ratios
were applied in the model.
Mortality rates have been shown to vary with hospital
admission and after discharge both in trials19 and in the
wider UK heart failure population,18 with those in hos-
pital and closer to discharge having higher death rates.
Following the approach of Thokala et al.,32 we reflected
this in the model using the hazard ratio for all-cause
mortality reported by Solomon et al.19 for patients
within 1–>24 months from discharge for their heart fail-
ure hospital admission. For hospital mortality, we
derived a hazard ratio for survival for patients in hos-
pital compared with within 30 days of discharge from
the UK Heart Failure Audit,18 which reports outcomes
from data on more than 73% of all English and Welsh
heart failure admissions. We calibrated the baseline mor-
tality rate so that the overall survival curves generated by
the model matched the survival curves based on param-
eters taken from the THIN analysis.30 We conservatively
assumed that the hazard ratio of death for subsequent
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Table 1. Model parameters and assumptions.
Parameter
Base-case
value Mean
Probabilistic
distribution
Standard
error Source
Mortality
Monthly probability of deatha 0.650% Beta Taylor et al.17
RR of death in hospital compared
with 30 days of discharge
1.5 Fixed Donkor et al.18
HR of mortality rate by months
since discharge
1 6.18 Lognormal 1.1364 Solomon et al.19
>1 4.39 Lognormal 1.1225
>3 3.54 Lognormal 1.1150
>6 3.11 Lognormal 1.0978
>12 2.46 Lognormal 1.0948
>24 1.93 Lognormal 1.1450
Hospital admission
Monthly probability of HF admission 2.04% Beta Cowie et al.20
Monthly probability of other cause admission 1.97% Beta Cowie et al.20
Average length of stay (days) 8 Fixed Donkor et al.18
Intervention effect
OR for HF admission: REACH-HF 0.56 Lognormal 2.03 Dalal et al.13
OR for HF admission: home-based CR 0.70 Lognormal 1.60 Meta-analysis (see Supplementary
Material online)
Duration of treatment effect Four years Fixed Assumption
Costs per patient
Admission HF £3873 Gamma Department of Health21
Admission other causes £2248 Gamma Zannad et al.,22 Department of Health21
Admission all cause £2901b Gamma Zannad et al.,22 Department of Health21
Ongoing monthly healthcare £96c Fixed Solomon et al.,19 Department of Health,21
Dalal et al.,23 Wong et al.,24
Michel et al.25
REACH-HF £418 Fixed Dalal et al.13
Home-based CR £477 Fixed Strategic Commissioning
Development Unit26
Utilities
Utility for HF patients at baseline 0.736 Fixed Kansal et al.27
HF hospital admission decrement –0.084 Beta 0.006 Kansal et al.27
Other cause hospital admission decrement –0.032 Beta 0.005 Kansal et al.27
Assumptions
Usual care was a no CR (either home- or centre-based) approach that included medical management according to national
and local guidelines, including specialist HF nurse care. Patients can be admitted for HF during any one-month cycle and
probability of admission was fixed for all patients at all times regardless of previous admissions.
First and subsequent HF hospitalisations give the same RR of death compared with no hospitalisation.
Other causes hospitalisations do not independently increase risk of death.
Rate of other causes hospitalisations do not change as a result of treatment allocation.
The cost and quality of life impact of being in any of the post-HF hospitalisation states (from one to 38þmonths after
discharge) were assumed to be the same.
aAt baseline, that is, never hospitalised or >38 months since last hospitalisation.
bWe estimate a per month cost for non-HF hospital admission based on a weighted average cost across four common types of non-HF admission
(other cardiovascular disease, renal function, hyperkalaemia and other), using data on proportions of each admission type reported in the Eplerenone in
Mild Patients Hospitalization and Survival Study in Heart Failure trial,22 combined with unit costs taken from the English National Schedule of Reference
Costs 2015/2016.
cBased on data for resource use by type, for people with HF: comprises £721 p.a. for drug costs, £33 p.a. for Accident and Emergency attendances,44
£101 p.a. for outpatient appointments and £302 p.a. for General Practitioner appointments monthly.45
RR: relative risk; HR: hazard ratio; REACH-HF: Rehabilitation Enablement in Chronic Heart Failure; HF: heart failure; OR: odds ratio; CR: cardiac
rehabilitation.
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hospital admissions was the same as for the first hospital
admission. We assumed that survival followed an expo-
nential curve, which has previously been shown to pro-
vide a good fit in this population.31,33
Costs
Costs were included in pounds sterling using the 2015/
2016 price year. The following costs were considered:
(i) home-based cardiac rehabilitation, (ii) costs associated
with heart failure hospital admission, (iii) costs associated
with other cause hospital admission, and (iv) primary and
secondary usual health care costs (excluding hospital
admission) associated with heart failure (see Table 1).
For intervention cost we use the UK NHS tariff for car-
diac rehabilitation of £477/patient)26 and the estimated
cost for delivery of the REACH-HF intervention of
£418/patient.13 This cost was applied to all patients at
the start of the model. Ongoing costs for usual care for
heart failure, primary care, secondary care, Accident &
Emergency department attendances and drug costs are
included for time spent in the heart failure non-hospital
admission state (£815/patient per year), informed by UK
national data for heart failure and the THIN dataset, a
large UK heart failure cohort study.17
The cost for hospital admission is based on data
from the English NHS National Schedule of
Reference Costs 2015/2016;26 for heart failure hospital
admission we use a weighted average cost of a single
hospital stay for the health resource groups EB03A to
D. The cost of non-heart failure hospital admissions is
a background cost in each cycle of the model, where
patients are alive with heart failure. We discounted
costs and QALYs at an annual rate of 3.5% in
accord with the NICE reference case.15
Health state values
We calculated QALYs by multiplying the health value
for the state by the time spent in that state. We use data
from the Systolic Heart failure treatment with the
inhibitor ivabradine Trial (SHIFT) to inform health
state values, applying a health state value of 0.736
for the heart failure health state, and a reduction (dec-
rement) of 0.084 where people experience a heart fail-
ure-related hospital admission.27 For non-heart failure
hospital admissions, we apply a decrement of 0.032 for
events. The impact of hospital events on health state
values is applied for the one-month cycle of hospital
admission after which individuals were assumed to
return to baseline values. Data from the SHIFT trial
were considered to be the most appropriate for our
model given the reporting of EQ-5D data for the
heart failure state and separately for a heart failure-
specific hospital admission.
Analysis
We present deterministic estimates of the cost per QALY
gained and use probabilistic sensitivity analysis and the
incremental net monetary benefit (iNMB) approach34,35
to address uncertainty around the results. The iNMB
approach uses parameters representing the maximum
amount that the Payer (i.e. NHS) is ‘willing to pay’ to
gain one QALY. We conservatively used the lower
NICE threshold value of £20,000 per QALY gained in
calculating iNMB.15 An iNMB value> 0 would indicate
that the intervention (home based cardiac rehabilitation)
is cost-effective. The cost-effectiveness acceptability
curve demonstrates how the willingness-to-pay threshold
affects the probability that the intervention is considered
cost-effective.35 Monte Carlo simulation was used to
draw a randomly selected estimate of each model par-
ameter from the distributions described in Table 1 and to
calculate the iNMB. Beta distributions represent the
uncertainty in the probability parameters (mortality,
hospital admission) and parameters for health state
values because these values are typically bounded at
zero and one. Log-normal distributions were used to
estimate uncertainty in hazard rates and ratios. We
used 5000 iterations to empirically estimate the uncer-
tainty surrounding the mean iNMB.
The key element of structural uncertainty identified
was heart failure-related mortality rates during admis-
sion and after discharge from hospital. This mechanism
allows any reductions in admission rate brought about
by the intervention to reduce overall mortality in the
cohort, with related cost savings and QALY gains esti-
mated. To test how sensitive the results are to the inclu-
sion of this element of model structure we included a
sensitivity analysis which uses a base mortality rate
(from the THIN cohort17) for all patients at all times,
regardless of hospital admission (SA1).
In addition, we included further deterministic ana-
lyses to test how sensitive the results were to the choice
of parameter as follows: the lowest hospital admission
rate from trials identified as sources of heart failure-spe-
cific admission (0.88% probability of admission per
month, based on the EMPHASIS trial22 (SA2); the
higher hospital admission rate from a large meta-analy-
sis of trials (2.83% probability of admission per month30
(SA3); survival based on previously-admitted patients in
the large combined data in Hospital Episode Statistics
and Office of National Statistics dataset31 (SA4); lower
mean intervention cost of £204/patient, based on the
lower bound of the 95% CI around estimated cost for
REACH-HF intervention (SA5); higher mean interven-
tion cost of £730, based on the upper bound of the 95%
CI around estimated cost for the REACH-HF interven-
tion;13 and assumption for home-based cardiac rehabili-
tation effect duration, at two years (SA7).
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Results
Base-case analysis
REACH-HF intervention. Over the HFrEF patient lifetime,
compared with usual care alone, the addition of
REACH-HF intervention was more costly (mean
£400/patient) and more effective (mean QALY 0.23)
with an estimated incremental cost effective ratio of
£1721/QALY (Table 2). There was a 78% probabil-
ity that REACH-HF was cost-effective at the
willingness to pay threshold of £20,000/QALY gained
(Supplementary Figure 3(a)).
Home-based cardiac rehabilitation. The estimated mean
gain in QALYs for home-based cardiac rehabilitation
compared with usual care was 0.16, and the estimated
mean incremental cost is £383/patient over the lifetime,
giving an estimated incremental cost ratio of per £2413
per QALY (Table 2). There was 73% probability that
home-based cardiac rehabilitation was cost-effective
compared with usual care, at £20,000/QALY gained
(Supplementary Figure 3(b)).
Sensitivity analyses
Sensitivity analyses (Supplementary Table 1(a) and (b))
indicate the base-case analyses to be robust and not
sensitive to changes in key structural assumptions in
the modelling framework or key input parameters (i.e.
mortality effect of hospital admission, probability of
hospital admission, probability of mortality, home-
based cardiac rehabilitation, duration of treatment
effect) for both REACH-HF and home-based cardiac
rehabilitation. Removing the increase in risk of mortal-
ity after hospital admission (SA1) resulted in home-
based cardiac rehabilitation dominating usual care,
with a reduction in costs (cost saving) and no difference
in QALYs. In this scenario, although QALY gains are
reduced, the costs associated with home-based cardiac
rehabilitation also reduce due to the absence of an
extended period of life expectancy and the absence of
the additional costs associated with extending lives in
the home-based cardiac rehabilitation group.
Discussion
Our estimates suggest that the addition of REACH-HF
intervention home-based cardiac rehabilitation to usual
care was cost-effective compared with usual care alone
in patients with HFrEF at a cost of £1721/QALY and a
78% likelihood of being cost-effective at the willingness
to pay threshold of £20,000 per QALY gained used by
policymakers in UK and many developed health-care
economies.15,36 Our cost-effectiveness estimates for
other home-based cardiac rehabilitation programmes
were similar. Our results were mainly driven by a reduc-
tion in heart failure-related hospitalisations with car-
diac rehabilitation.
Two recent systematic reviews of cost-effectiveness
of cardiac rehabilitation have been published.4,37
Based on the results of these reviews, this is the first
published full economic evaluation of a specific home-
based programme (REACH-HF) and home-based car-
diac rehabilitation programmes more broadly in
patients with heart failure. However, our findings are
consistent with previously economic evaluations in
heart failure comparing centre-based cardiac rehabili-
tation with no-cardiac rehabilitation control. Using
extrapolated outcome survival data from a single
centre randomised controlled trial, Georgiou and col-
leagues reported an incremental cost-effectiveness ratio
of US$2500 per life-year gained for an exercise training
programme at a 10-year time horizon based on the US
healthcare perspective.38 Using a variety of modelling
assumptions and data at 2.5 years’ follow-up from the
large HF-ACTION trial undertaken across 82 centres
across the USA, Canada and France, Reed et al. esti-
mated that the cost-effectiveness of exercise training
could vary from dominant (cost saving and more
QALYs gained) to US$43,141/QALY.39 Based on
data from an exercise-based cardiac rehabilitation pro-
gramme in Colombia, using modelling, Rinco´n et al.
estimated an incremental cost per QALY of US$1065/
Table 2. Results of cost-effectiveness analyses: REACH-HF intervention and home-based CR versus usual care.
Discounted costs £,
mean (95% CI)
Discounted QALYs,
mean (95% CI)
ICER (£ per
QALY gained)
vs. usual care
% simulations
with iNMB> £0
Usual care alone £15,051 (£13,844 to £16,289) 4.24 (4.05 to 4.43)
REACH-HF intervention plus usual care £15,452 (£14,240 to £16,780) 4.47 (3.83 to 4.91) £1721 78%
Home-based CR plus usual care £15,444 (£14,278 to £16,781) 4.40 (3.89 to 4.77) £2413 73%
CR: cardiac rehabilitation; CI: confidence interval; QALY: quality-adjusted life-year; ICER: incremental cost-effectiveness ratio; iNMB: incremental net
monetary benefit; REACH-HF: Rehabilitation Enablement in Chronic Heart Failure
6 European Journal of Preventive Cardiology 0(00)
QALY at five years.40 Finally, a Markov model-based
analysis by Ku¨hr et al. reported a cost per QALY of
29,498 international dollars for a hypothetical cohort of
heart failure patients attending an outpatient cardiac
rehabilitation programme from the perspective of the
Brazilian Public Healthcare System over a 10-year time
horizon.41 Notwithstanding the challenge of directly
comparing costs across international jurisdictions and
whilst these incremental cost effectiveness ratios vary in
their magnitude, they have broadly been interpreted by
study authors as demonstrating cardiac rehabilitation
to be a cost-effective strategy in patients with HFrEF.
Although not recruiting heart failure patients, the
recently published FIT@Home study also showed that
home-based cardiac rehabilitation can be a cost-effective
strategy.42 This study randomised 90 low to moderate
risk patients following an acute coronary syndrome or
revascularisation to three months of either home-based
training with telemonitoring guidance or centre-based
training. Average healthcare costs were lower in the
home-based group (E437 per patient) and had probabil-
ity of being cost-effective of 97% and 75% at willingness-
to-pay of E0 and E100,000 per QALY, respectively.
Strengths and limitations
This study uses cost and outcome data from a high
quality multicentre randomised controlled trial of
REACH-HF in patients with HFrEF with multiple
comorbidities reflective of the clinical setting.13 The
use of Markov modelling overcomes the limitations of
a within trial economic evaluation, allowing the model-
ling of costs and outcomes over the longer term of
patient lifetime and the assessment of the long-term
cost effectiveness beyond the trial period. The use of
longer time-horizons is also more compatible with the
chronic nature of heart failure and in accord with
NICE methodology guidance.15 We use high quality
data on mortality from a large cohort study consistent
with the setting for our economic analysis. Given the
variation of hospital admission data, we use a UK data-
set in our base-case analysis. However, use was made of
alternative data sources in sensitivity analyses.
A key limitation was that the REACH-HF trial was
not powered to detect differences in hospitalisations
between arms. However, we sought to overcome this
by undertaking a meta-analysis where we included data
from two other randomised trials that tested different
versions of home-based cardiac rehabilitation.
Furthermore, our probabilistic sensitivity analysis expli-
citly took account of the uncertainty in the data inputs
to the model. Nevertheless, future trials of cardiac
rehabilitation need to consistently collect and report
the outcome of patient hospitalisation. We used a
simple Markov modelling approach, and whilst this
approach is consistent with the wider literature on eco-
nomic models in heart failure, we acknowledge it
assumes no additional impact from multiple admissions.
Whereas in real life patients may suffer from worsening
HRQoL after further subsequent hospital stays, this
conservative assumption may have led us to underesti-
mate the cost-effectiveness of REACH-HF and home-
based cardiac rehabilitation. We use heart failure-related
hospital admissions as the main event of interest in the
assessment of home-based cardiac rehabilitation. The
absence of any specific modelling of effects on other
(non-heart failure specific) cause of hospital admissions
may be a limitation of the modelling, although is also
likely due to a conservative assumption as cardiac
rehabilitation may positively impact on the risk of
admissions due to other cardiovascular related events,
such as myocardial infarction or stroke.
Clinical implications
This cost-utility analysis indicates that the REACH-HF
intervention and home-based cardiac rehabilitation pro-
grammes are likely to be cost-effective for patients for
HFrEF. These economic results have considerable
policy relevance given current low levels of uptake of car-
diac rehabilitation for heart failure across international
healthcare systems.43 In order to improve cardiac rehabili-
tation participation there have been calls for the develop-
ment of cardiac rehabilitation programmes that provide
an alternative to supervised outpatient programmes, such
as home-based programmes.8,9,23 The results of this ana-
lysis are therefore timely and show that home-based car-
diac rehabilitation programmes provide a cost-effective
alternative use of healthcare resources. The systematic
review of home versus centre-based cardiac rehabilitation
by Wong et al. concluded that as costs and outcomes of
home-based versus supervised centre-based CR were no
different, the choice of the mode of delivery (home- versus
centre-based) should be left to healthcare providers and
patients.24 This is further reinforced by the recently
updated UK clinical guidelines for the management of
heart failure, that patients should be offered CR ‘in a
format and setting (at home, in the community or in
the hospital) that is easily accessible for the person’.7
Conclusion
Over the lifetime of the HFrEF patient, our cost-utility
analyses suggest that REACH-HF and home-based
cardiac rehabilitation are cost-effective treatment
options in the setting of the UK health service. These
findings should encourage healthcare providers and
purchasers to fund home-based cardiac rehabilitation
programmes to improve access and promote participa-
tion in cardiac rehabilitation for people with heart
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failure and thereby improve the HRQoL and morbidity
of this population.
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